XNAS · Biotechnology
Last stored close · Nov 6, 2026
Close · Nov 6, 2026
$16.33+15.08%
Model Target
—
not published for this name
Implied upside
—
vs the model target
Valuation methods
—
no method met the standard
TickerWhale Score
—
Not scored in the latest run — the model needs every factor family, and one was unavailable for this name.
Score components
TickerWhale View
No narrated read for this name yet — the deterministic factors still carry the analysis.
What helps
- Technical
- Risk
What to watch
- Quality & growth
Quality & growth
30%14Weak
- Revenue growth n/a
- EPS growth n/a
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
Return on equity (industry)Top 95%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
51/100Moderate
Weighted composite of momentum, trend, relative strength, oscillators, volatility, drawdown and liquidity — not yet ranked against the universe in this run · 25% of the TickerWhale Score
Classic chart indicators
Buy
3 buy · 2 sell · 3 neutral of 8 votes
TickerWhale reads SMMT's technical setup as middling at 51/100, not yet ranked against the universe in this run. Classic chart indicators lean buy — they read this stock on its own over days, where our score ranks it against every covered name over months, so the two often part company.
Moving averages
8 / 9constructive
- vs 200-day+1.2%
- vs 50-day+0.5%
Momentum
Mixed
- RSI (14)53 · neutral
- Stochasticsell
- CCIneutral
- Williams %Rsell
Trend
Mixed
- ADX (14) trend strength9· weak trend
- MACD (12,26,9)buy(histogram 0.020)
How the classic verdict is reached
Moving averages (9) agree on buy — 8 buy vs 0 sell — and carry one vote between them.
Oscillators (7) vote individually: 2 buy · 2 sell · 3 neutral.
Result — 3 buy vs 2 sell of 8 votes = Buy. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-11-06 · revised_latestValuation multiples
- P/E (TTM)-14.8 · TTM loss
- P/S (TTM)—
- P/B20.2
- EV/EBITDA—
- EV/Sales—
- PEG—
Profitability & returns
- Gross margin—
- Net margin—
- ROE-145.6%
- Debt/Equity0.00
Growth
- Revenue growth (YoY)—
- EPS growth (YoY)—
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $12.7B
Fundamentals history
Reported statement totals across recent periods.
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target — Under Review
Our valuation methods do not currently agree closely enough for us to publish a single target for this company. We would rather say so than print a number we cannot stand behind. The TickerWhale Score still reflects quality, growth and momentum.
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SMMTCurrentSummit Therapeutics | — | 51 | -14.8 | — | 20.2 | — | $16.33 | +15.08% | — | ||
| EXELExelixis | 81 | 87 | 21.0 | — | 9.8 | 7.3 | $69.57 | +1.25% | +9.2% | ||
| KNSAKiniksa Pharmaceuticals International plc. - | 80 | 81 | 97.0 | — | 12.0 | 9.2 | $93.86 | +6.25% | +58.9% | ||
| INCYIncyte | 77 | 67 | 15.5 | — | 3.9 | 3.6 | $119.65 | +1.39% | +26.9% | ||
| TGTXTG Therapeutics | 77 | 82 | 21.3 | — | 15.6 | 12.1 | $59.83 | +3.18% | +76.1% | ||
| THCTenet Healthcare | 77 | 78 | 10.6 | — | 5.1 | 1.6 | $283.33 | -1.09% | +7.5% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.